VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALKSAlkermes plc
$55.08$9.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksALKSFinancials

Alkermes plc (ALKS) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly inconsistent, with a 28.2% increase in 2026Q1 failing to prevent a net loss of $66.5M due to rising SG&A expenses.

ALKS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97Mar'96
Sales/Revenue1.56B1.48B1.56B1.66B1.11B1.17B1.04B1.17B1.09B903.37M745.69M628.34M618.79M575.55M575.55M389.98M186.64M178.28M326.84M240.72M239.97M166.6M76.13M39.05M47.27M54.1M56.03M22.92M33.9M31.37M19.83M
Revenue Growth %3.21%-5.25%-6.36%49.61%-5.28%13%-11.29%7.01%21.13%21.15%18.68%1.54%7.51%0%47.59%108.95%4.69%-45.45%35.78%0.31%44.04%118.85%94.92%-17.37%-12.63%-3.44%144.45%-32.39%8.08%58.2%24.55%
Cost of Goods Sold147.26M196.46M245.33M253.04M218.07M197.32M178.32M180.38M176.42M154.75M132.12M138.99M175.83M310.48M170.47M127.58M52.19M49.44M43.4M40.68M45.21M23.49M16.83M19.04M10.91M0-7.7M-6.43M-21.6M00
COGS % of Revenue-13.31%15.75%15.21%19.61%16.81%17.17%15.41%16.12%17.13%17.72%22.12%28.42%53.94%29.62%32.71%27.96%27.73%13.28%16.9%18.84%14.1%22.11%48.74%23.08%--13.74%-28.06%-63.72%--
Gross Profit1.02B1.28B1.31B1.41B893.73M976.43M860.44M990.56M917.85M748.63M613.57M489.35M442.96M265.07M405.08M262.4M134.46M128.84M283.44M200.04M194.76M143.11M59.29M20.02M36.36M063.73M29.35M55.5M00
Gross Margin %65.42%86.69%84.25%84.79%80.39%83.19%82.83%84.59%83.88%82.87%82.28%77.88%71.58%46.06%70.38%67.29%72.04%72.27%86.72%83.1%81.16%85.9%77.89%51.26%76.92%-113.74%128.06%163.72%--
Gross Profit Growth %--2.5%-6.95%57.81%-8.47%13.48%-13.14%7.92%22.61%22.01%25.39%10.47%67.11%-34.56%54.38%95.16%4.36%-54.54%41.69%2.71%36.09%141.37%196.2%-44.94%--100%117.12%-47.11%---100%
Operating Expenses1.15B1.03B891.66M996.25M899.82M878.68M972.87M1.17B1.02B896.53M822.24M713.65M530.1M167.61M323.27M350.68M180.09M171.88M148.49M202.83M183.71M129.45M132.67M116.92M118.58M116.48M93.63M105.29M100.9M42.32M37.24M
OpEx % of Revenue-69.48%57.24%59.89%80.93%74.86%93.66%99.58%92.94%99.24%110.26%113.58%85.67%29.12%56.17%89.92%96.49%96.41%45.43%84.26%76.56%77.7%174.27%299.38%250.88%215.3%167.12%459.35%297.64%134.92%187.84%
Selling, General & Admin794.41M701.52M645.24M689.75M590.75M549.61M538.83M599.45M526.41M421.58M374.13M311.56M199.91M125.76M125.76M137.63M82.85M76.51M59.01M59.51M66.4M40.38M29.5M26.03M26.7M24.39M17.16M44.37M30.8M10.56M7.69M
SG&A % of Revenue-47.53%41.42%41.47%53.13%46.83%51.87%51.19%48.11%46.67%50.17%49.58%32.31%21.85%21.85%35.29%44.39%42.92%18.05%24.72%27.67%24.24%38.75%66.65%56.48%45.08%30.63%193.59%90.86%33.66%38.78%
Research & Development355.49M323.96M245.33M270.81M272.7M290.92M394.59M512.83M425.41M412.89M387.15M344.4M272.04M6.54M140.01M141.89M97.24M95.36M89.48M125.27M117.31M89.07M91.64M91.1M85.39M92.09M68.77M54.48M48.5M31.76M29.55M
R&D % of Revenue-21.95%15.75%16.28%24.53%24.79%37.99%43.8%38.88%45.71%51.92%54.81%43.96%1.14%24.33%36.38%52.1%53.49%27.38%52.04%48.89%53.46%120.38%233.26%180.65%170.22%122.74%237.7%143.07%101.26%149.06%
Other Operating Expenses001.1M35.69M36.36M38.15M39.45M53.76M65.17M62.06M60.96M57.69M58.15M1.78M57.5M71.16M00018.05M0011.53M-208.15K6.5M07.7M6.43M21.6M00
Operating Income191.88M253.96M420.64M414.12M-6.09M97.75M-112.43M-175.48M-99.13M-147.9M-208.66M-224.3M-87.14M81.81M81.81M-88.28M-45.63M-43.03M134.96M-2.79M11.04M13.66M-73.38M-96.9M-82.22M-62.38M-29.91M-75.93M-45.4M-10.95M-17.42M
Operating Margin %12.28%17.21%27%24.9%-0.55%8.33%-10.82%-14.99%-9.06%-16.37%-27.98%-35.7%-14.08%14.21%14.21%-22.64%-24.45%-24.14%41.29%-1.16%4.6%8.2%-96.39%-248.12%-173.96%-115.3%-53.38%-331.29%-133.92%-34.92%-87.84%
Operating Income Growth %--39.63%1.57%6901.15%-106.23%186.94%35.93%-77.02%32.98%29.12%6.97%-157.39%-206.52%0%192.67%-93.47%-6.03%-131.89%4938.9%-125.26%-19.17%118.62%24.28%-17.85%-31.82%-108.57%60.61%-67.25%-314.49%37.11%-37.1%
EBITDA211.63M281.12M449.17M489.05M71.77M176.4M-30.57M-95.07M4.53M-49.38M-114.41M-138.71M10.94M155.56M155.56M-40.4M-36.98M-18.01M145.22M9.35M23.03M24.54M-62.76M-85.99M-72.9M-51.88M-22.21M-69.5M-23.8M-6.16M-14.85M
EBITDA Margin %13.55%19.05%28.84%29.4%6.46%15.03%-2.94%-8.12%0.41%-5.47%-15.34%-22.07%1.77%27.03%27.03%-10.36%-19.81%-10.1%44.43%3.88%9.6%14.73%-82.44%-220.17%-154.24%-95.89%-39.64%-303.24%-70.21%-19.64%-74.9%
EBITDA Growth %-49.49%-37.41%-8.15%581.38%-59.31%676.97%67.84%-2197.66%109.18%56.84%17.52%-1367.52%-92.97%0%485.09%-9.24%-105.35%-112.4%1453.34%-59.41%-6.14%139.1%27.02%-17.95%-40.53%-133.57%68.04%-192.03%-286.33%58.52%-43.46%
D&A (Non-Cash Add-back)19.74M27.16M28.53M74.93M77.86M78.65M81.85M80.41M103.66M98.52M94.26M85.6M98.09M73.75M73.75M47.88M8.65M25.03M10.27M12.14M11.99M10.88M10.62M10.91M9.32M10.5M7.7M6.43M21.6M4.79M2.57M
EBIT278.24M303.73M466.33M444.55M-18.09M98.95M-87.88M-183.46M-111.53M-131.27M-199.5M-210.76M-599K55.52M84.44M-86.28M-43.19M-38.73M144.77M3.63M11.04M13.66M-61.85M-97.11M-75.73M-62.38M-29.91M-75.93M-45.4M-10.95M-17.42M
Net Interest Income22.89M33.03M19.87M7.82M-5.41M-8.81M-1.7M375K-6.2M-7.36M-11.14M-9.92M-11.46M-48.15M-48.15M-26.59M-570K-1.31M-2.36M000000000000
Interest Income43.7M45.3M42.45M30.85M7.63M2.41M6.96M13.98M9.24M4.65M3.75M3.33M1.97M841K841K1.52M2.73M4.67M11.4M000000000000
Interest Expense-8.62M12.28M22.58M23.03M13.04M11.22M8.66M13.6M15.44M12.01M14.89M13.25M13.43M48.99M48.99M28.11M3.3M5.97M13.76M000000000000
Other Income/Expense12.15M37.49M23.11M7.4M-25.04M-10.02M15.89M-21.58M-27.84M4.63M-5.72M296K73.11M963K-46.37M-26.11M-860K-1.67M-3.94M175.62M-499K-13.66M-1.79M96.9M-24.68M1.02M13.04M75.93M45.4M10.95M17.42M
Pretax Income204.03M291.45M443.75M421.52M-31.13M87.73M-96.54M-197.06M-126.97M-143.27M-214.39M-224M-14.03M35.44M35.44M-114.39M-46.49M-44.7M131.01M172.83M10.54M0-75.17M0-106.9M-61.35M-16.87M0000
Pretax Margin %13.06%19.75%28.49%25.34%-2.8%7.47%-9.29%-16.83%-11.6%-15.86%-28.75%-35.65%-2.27%6.16%6.16%-29.33%-24.91%-25.07%40.08%71.8%4.39%--98.74%--226.16%-113.41%-30.11%----
Income Tax51.31M49.79M71.61M-97.64M2.02M11.33M14.32M-436K12.34M14.67M-5.94M3.16M16.03M10.46M10.46M-714K-951K-5.08M507K5.85M1.1M0000000000
Effective Tax Rate %25.15%17.08%16.14%-23.16%-6.5%12.91%-14.84%0.22%-9.72%-10.24%2.77%-1.41%-114.28%29.51%29.51%0.62%2.05%11.35%0.39%3.39%10.41%-0%-0%0%0%----
Net Income152.72M241.66M367.07M355.76M-158.27M-48.17M-110.86M-196.62M-139.31M-157.94M-208.44M-227.16M-30.06M24.98M24.98M-113.68M-45.54M-39.63M130.5M166.98M9.45M3.82M-75.17M-102.38M-106.9M-61.35M-16.87M-68.05M-41.1M-12.58M-18.8M
Net Margin %9.78%16.37%23.57%21.39%-14.24%-4.1%-10.67%-16.79%-12.73%-17.48%-27.95%-36.15%-4.86%4.34%4.34%-29.15%-24.4%-22.23%39.93%69.37%3.94%2.29%-98.74%-262.16%-226.16%-113.41%-30.11%-296.89%-121.24%-40.11%-94.81%
Net Income Growth %-56.7%-34.16%3.18%324.78%-228.57%56.55%43.62%-41.14%11.8%24.23%8.24%-655.67%-220.33%0%121.98%-149.62%-14.92%-130.36%-21.84%1667.91%147.38%105.08%26.58%4.22%-74.23%-263.71%75.21%-65.57%-226.65%33.07%-36.74%
Net Income (Continuing)152.72M241.66M372.14M519.16M-33.15M76.4M-110.86M-196.62M-139.31M-157.94M-208.44M-227.16M-30.06M23.53M24.98M-113.68M-45.54M-39.63M130.5M166.98M9.45M3.82M-75.17M-102.38M-106.9M-61.35M-16.87M-68.05M-41.1M-12.58M-18.8M
Discontinued Operations00-5.07M-163.4M-125.11M-124.57M0000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)0.921.432.172.10-0.97-0.30-0.70-1.25-0.90-1.03-1.38-1.52-0.210.180.18-0.99-0.48-0.421.361.620.090.04-0.83-1.25-1.70-0.96-0.43-1.52-0.99-0.28-0.51
EPS Growth %-56.94%-34.1%3.33%316.49%-223.33%57.14%44%-38.89%12.62%25.36%9.21%-623.81%-216.67%0%118.18%-106.25%-14.29%-130.88%-16.05%1700%125%104.82%33.6%26.47%-77.08%-123.26%71.71%-53.54%-253.57%45.1%-8.51%
EPS (Basic)-1.472.222.14-0.97-0.30-0.70-1.25-0.90-1.03-1.38-1.52-0.210.190.19-0.99-0.48-0.421.371.660.100.04-0.83-1.25-1.70-0.96-0.43-1.52-0.99-0.28-0.51
Diluted Shares Outstanding166.2M168.74M169.2M169.73M163.74M160.94M158.8M157.05M155.11M153.41M151.48M149.21M145.27M137.1M137.1M114.7M95.61M94.84M96.25M102.92M103.35M97.38M90.09M82.08M64.37M63.67M59.86M51.01M49.12M46.04M36.58M
Basic Shares Outstanding166.2M164.7M165.39M166.22M163.74M160.94M158.8M157.05M155.11M153.41M151.48M149.21M145.27M131.71M131.71M114.7M95.61M94.84M95.16M100.74M99.24M91.02M90.09M82.08M64.37M63.67M55.75M51.01M49.12M46.04M36.58M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Royalty stream arbitration uncertainty

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Top Line Growth Remains Volatile

As reported in recent financial filings, Alkermes experienced a 28.2% revenue increase in 2026Q1, yet this follows a period of inconsistent performance where quarterly growth rates fluctuated significantly, suggesting that the company's reliance on milestone payments and royalty streams creates an inherently unpredictable revenue trajectory.

The recent revenue spike appears heavily influenced by the timing of partner-related payments rather than purely organic product demand. Investors should monitor whether the commercial scaling of Lybalvi can provide a more stable, predictable growth floor to offset the inherent lumpiness of the royalty-heavy business model.

Structural Margin Resilience Under Pressure

Based on the provided income statement data, Alkermes maintains a robust gross margin profile, consistently hovering above 83%, which reflects the high-margin nature of its royalty-based revenue streams despite recent operational cost fluctuations that have pressured the company's bottom-line profitability in the most recent quarter.

The ability to sustain high gross margins suggests strong pricing power within the specialized CNS market. However, the compression of operating margins to negative levels in 2026Q1 warrants investigation into whether this is a temporary spike in SG&A or a sign of rising commercialization costs for newer assets.

Operating Leverage Efficiency Remains Elusive

According to the latest quarterly results, Alkermes' operating income swung to a loss of $48.3M, indicating that the company has struggled to achieve meaningful operating leverage as SG&A expenses continue to outpace the growth of gross profit in the current fiscal environment.

The disconnect between gross profit generation and operating income suggests that the company's fixed cost base, particularly in sales and marketing, remains high relative to current revenue levels. This lack of scalability may imply that the company is currently in a heavy investment phase for its newer product portfolio.

Earnings Quality Impacted by Volatility

Analysis of the income statement reveals that net income has been subject to significant swings, with the 2026Q1 net loss of $66.5M highlighting the impact of non-operating items and potential accounting adjustments that complicate the assessment of the company's true underlying earnings power.

The presence of significant quarterly fluctuations in net income, coupled with the recent $72.4M negative stock-based compensation adjustment in 2025Q4, suggests that reported EPS may not always reflect core operational performance. Investors should be cautious of relying on headline earnings without adjusting for these non-recurring or accounting-driven distortions.

Sustainability of Royalty Revenue Streams

While the company's royalty-heavy model provides high margins, the ongoing arbitration regarding the Invega franchise, as noted in recent disclosures, presents a material risk that could lead to a sudden and significant contraction in the company's most profitable revenue segment moving forward.

Short-term observers may focus on the potential for a 'royalty cliff' if legal outcomes favor partners, which would fundamentally alter the company's cash flow profile. The reliance on these high-margin, low-cost streams masks the true operational cost of the proprietary product business, which may be less profitable than the consolidated figures suggest.

ALKS — Frequently Asked Questions

Quick answers to the most common questions about buying ALKS stock.

What was Alkermes plc's (ALKS) revenue in 2025?

For fiscal year 2025, Alkermes plc (ALKS) reported total revenue of $1.48B. This represents a 7343.9% increase compared to $19.8M in 1996.

Is Alkermes plc (ALKS) profitable?

Alkermes plc (ALKS) is profitable, generating $241.7M in net income for the fiscal year ending 2025 with a net profit margin of 16.4%.

What is Alkermes plc's operating profit margin?

Alkermes plc (ALKS) reported an operating income of $254.0M, resulting in an operating profit margin of 17.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Alkermes plc's gross profit and gross margin?

Alkermes plc (ALKS) generated $1.28B in gross profit for the year, representing a gross profit margin of 86.7%. This demonstrates the company's core pricing power and production efficiency.